In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, describes how double-blind double-dummy design, site reminders, and ...

Viridian Therapeutics announced that it has completed enrollment for the Phase III REVEAL-1 (NCT06812325) and REVEAL-2 (NCT06625398) trials evaluating VRDN-003 in patients with active and chronic ...

In this episode of the ACT Brief, we spotlight an earlier interview with Ron Lanton, partner at Lanton Law, in which he ...

An interim analysis of the TULIP-SC trial found that weekly subcutaneous delivery of Saphnelo significantly reduced disease ...

A quick look at FDA’s 2025 transparency moves, what CRLs are (and aren’t), how FAERS works and its limits, who can report, and where the agency is applying AI.

On the clinical side, as a CRO and clinical data partner, IQVIA can access all Veeva applications for running trials, including study builds with Veeva EDC. This integration aims to simplify workflows ...

Preliminary results from an ongoing Phase IV trial showed that Moderna’s updated 2025-2026 Spikevax vaccine generated a ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

The IDeate-Lung01 trial showed a 48% confirmed response rate with Merck’s B7-H3 directed antibody-drug conjugate in previously treated extensive-stage small cell lung cancer, with durable benefit ...

Generative artificial intelligence (AI) has absolutely exploded onto the scene. It's become a top strategic priority in the ...

Site networks can be a powerful engine for this kind of change. When built on collaboration, not control, and focused on capability over conformity, they allow more sites to engage in research, more ...

ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...